Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome.
Publication/Presentation Date
1-1-2016
Abstract
Two infants with retinoblastoma and 13q syndrome with multiorgan system anomalies were treated with targeted intra-arterial chemotherapy (IAC) using one-to-three cycles of melphalan 5 mg to avoid systemic chemotherapeutic side effects. Both patients showed good response, with tumor control and no systemic chemotherapy side effects. Of the treatment modalities currently available, IAC may represent an optimal balance between tumor extermination and adverse drug reactions in this patient population with classically reduced multiorgan reserve.
Volume
9
Issue
3
First Page
164
Last Page
166
ISSN
0974-620X
Published In/Presented At
Dillon, A. B., Douglass, A., Jabbour, P., & Shields, C. L. (2016). Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome. Oman journal of ophthalmology, 9(3), 164–166. https://doi.org/10.4103/0974-620X.192278
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
27843232
Department(s)
Administration and Leadership
Document Type
Article